ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 803

Interferon-Alpha Mediated Lowering of Pentraxin-3 Levels in Systemic Lupus Erythematosus?

Lina Wirestam1, Helena Enocsson2, Christopher Sjöwall2, Thomas Skogh2, Maija-Leena Eloranta3, Lars Rönnblom3 and Jonas Wetterö2, 1Department of Clinical & Experimental Medicine, Rheumatology/AIR, Linkoping, Sweden, 2Department of Clinical and Experimental Medicine, Rheumatology/AIR, Linköping, Sweden, 3Medical Sciences, Rheumatology clinic, Uppsala, Sweden

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Acute-phase reactants, Biomarkers, interferons and leukocytes, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

The type I interferon (IFN) system is important in the pathogenesis of systemic lupus erythematosus (SLE). We have previously shown an inhibitory effect of IFN-α on interleukin (IL)-6/IL-1 mediated hepatocyte production of C-reactive protein (CRP) in vitro as well as in vivo, partly explaining the poor correlation between disease activity and circulating CRP in SLE. The non-hepatic long pentraxin 3 (PTX3) belongs to the same protein family, and shares some key properties with CRP regarding the handling of cellular debris. This study aimed to evaluate PTX3 as a potential biomarker in SLE, as well as to assess its possible interference with IFN-α by targeting levels in patients and in mechanistic studies on isolated leukocytes.

Methods:

Sera from 243 SLE patients meeting the 1982 ACR and/or the 2012 SLICC classification criteria, and 100 healthy controls were analysed for PTX3 (ELISA) and IFN-α (dissociation-enhanced lanthanide fluoroimmunassay). Disease activity (SLEDAI-2K) varied considerably among the SLE patients at the time point of blood sampling. The majority had established SLE, whereas 9% had recent onset disease.

Neutrophils and peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation of heparinised blood from healthy donors. Leukocyte PTX3 production was stimulated by IL-1β, tumour necrosis factor (TNF), lipopolysaccharide (LPS), and IFN-α. Cell supernatants were analysed for PTX3 by ELISA.

Results:

PTX3 levels were significantly lower in SLE patients (median 2.5 ng/ml) compared to healthy controls (median 4.5 ng/ml); (p <0.0001). PTX3 levels were not correlated with SLEDAI-2K, but with leukocyte-associated variables. Cross-sectional analysis revealed a slight negative correlation between PTX3 and IFN-α (r=-0.154, p=0.017). Patients with no detectable IFN-α (<1 U/ml) had however significantly higher levels of PTX3 (median 2.7 ng/ml) compared to patients with IFN-α >1 U/ml (median 2.1 ng/ml; p=0.01).

In vitro experiments showed IFN-α dependent inhibition of stimulated PTX3 production in healthy blood donor PMBC. No such effect was observed in neutrophils. 

Conclusion:

Average PTX3 levels are lower in SLE patients compared to controls. IFN-α partly inhibits leukocyte PTX3 production in vitro, and its inverse correlation with PTX3 in SLE implies that IFN-α mediated suppression of PTX3 synthesis also occurs in vivo. Since pentraxins have a suggested protective role in SLE, these findings are of interest regarding the handling of apoptotic material and the pathogenesis of SLE.


Disclosure: L. Wirestam, None; H. Enocsson, None; C. Sjöwall, None; T. Skogh, None; M. L. Eloranta, None; L. Rönnblom, None; J. Wetterö, None.

To cite this abstract in AMA style:

Wirestam L, Enocsson H, Sjöwall C, Skogh T, Eloranta ML, Rönnblom L, Wetterö J. Interferon-Alpha Mediated Lowering of Pentraxin-3 Levels in Systemic Lupus Erythematosus? [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/interferon-alpha-mediated-lowering-of-pentraxin-3-levels-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interferon-alpha-mediated-lowering-of-pentraxin-3-levels-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology